Pfizer Beats Analyst Estimates on EPS
Pfizer (NYS: PFE) reported earnings on Nov. 1. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Pfizer missed estimates on revenues and beat slightly on earnings per share.
Compared to the prior-year quarter, revenue contracted significantly and GAAP earnings per share shrank.
Gross margins expanded, operating margins shrank, net margins increased.
Pfizer chalked up revenue of $13.98 billion. The 11 analysts polled by S&P Capital IQ anticipated a top line of $14.68 billion on the same basis. GAAP reported sales were 19% lower than the prior-year quarter's $17.19 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.53. The 14 earnings estimates compiled by S&P Capital IQ forecast $0.52 per share. GAAP EPS of $0.42 for Q3 were 13% lower than the prior-year quarter's $0.48 per share. (The prior-year quarter included $0.17 per share in earnings from discontinued operations.)
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 80.9%, 190 basis points better than the prior-year quarter. Operating margin was 23.6%, 880 basis points worse than the prior-year quarter. Net margin was 23.0%, 130 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $14.82 billion. On the bottom line, the average EPS estimate is $0.44.
Next year's average estimate for revenue is $59.51 billion. The average EPS estimate is $2.19.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 5,458 members out of 6,049 rating the stock outperform, and 591 members rating it underperform. Among 1,539 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 1,440 give Pfizer a green thumbs-up, and 99 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pfizer is outperform, with an average price target of $26.82.
Can your retirement portfolio provide you with enough income to last? You'll need more than Pfizer. Learn about crafting a smarter retirement plan in "The Shocking Can't-Miss Truth About Your Retirement." Click here for instant access to this free report.
- Add Pfizer to My Watchlist.
The article Pfizer Beats Analyst Estimates on EPS originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.